Stockscreener 앱 받기
0.649
3.03%
0.0191
전일 마감가:
$0.6299
열려 있는:
$0.63
하루 거래량:
178.13K
Relative Volume:
1.04
시가총액:
$11.27M
수익:
$4.03M
순이익/손실:
$24.32M
주가수익비율:
-0.1509
EPS:
-4.3008
순현금흐름:
$-45.76M
1주 성능:
-4.82%
1개월 성능:
-4.56%
6개월 성능:
-43.07%
1년 성능:
-65.48%
1일 변동 폭
$0.6006
$0.6676
1주일 범위
$0.6006
$0.78
52주 변동 폭
$0.55
$1.96
Pavmed Inc Stock (PAVM) Company Profile
명칭
Pavmed Inc
전화
(212) 949-4319
주소
360 MADISON AVENUE, NEW YORK, NY
PAVM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PAVM
Pavmed Inc
|
0.649 | 11.62M | 4.03M | 24.32M | -45.76M | -4.3008 |
|
ABT
Abbott Laboratories
|
134.80 | 231.82B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
106.04 | 152.18B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
394.21 | 145.57B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
86.44 | 107.07B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
78.00 | 43.22B | 5.54B | 4.18B | 623.10M | 7.00 |
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-05 | 개시 | Ascendiant Capital Markets | Buy |
| 2018-06-28 | 개시 | Maxim Group | Buy |
Pavmed Inc 주식(PAVM)의 최신 뉴스
PAVmed Inc. (NASDAQ:PAVM) Q1 2025 Earnings Call Transcript - Insider Monkey
PAVmed Inc (PAVM) Q1 2025 Earnings Call Highlights: Strategic Expansion and Financial Fortification - Yahoo Finance
Pavmed Inc. Reports Turnaround with Strong Q1 Earnings - TipRanks
PAVmed Q1 2025 slides: net income soars amid strategic restructuring - Investing.com
Earnings call transcript: PAVmed’s Q1 2025 sees strong net income and strategic shifts - Investing.com
Transcript : PAVmed Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
PAVmed Inc Q1 2025 Earnings: Revenue Surges to $0.8 Million, Bea - GuruFocus
PAVmed Reports Q1 2025 Financial Results and Updates - TipRanks
PAVmed Provides Business Update and Reports First Quarter 2025 F - GuruFocus
PAVmed Q1 Earnings: $40M Cash Runway Powers Multi-Subsidiary Growth and Biopharma Entry Plans - Stock Titan
PAVmed (PAVM) Q1 Earnings Beat with Improved EPS and Revenue - GuruFocus
PAVmed Inc. SEC 10-Q Report - TradingView
Lucid Diagnostics Reports Q1 2025 Financial Results - TipRanks
Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results - Nasdaq
PAVmed (PAVM) to Release Quarterly Earnings on Thursday - Defense World
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025 - Kilgore News Herald
PAVmed to Hold a Business Update Conference Call and Webcast on - GuruFocus
PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025 - The Victoria Advocate
PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025 | PAVM Stock News - GuruFocus
PAVmed Sets Key Q1 2025 Earnings Call: MedTech Growth Strategy and Financial Results Coming May 15 - Stock Titan
PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
PAVmed switches to new accounting firm post-acquisition - Investing.com Australia
PAVmed switches to new accounting firm post-acquisition By Investing.com - Investing.com South Africa
PAVmed, Lucid post encouraging results from EsoGuard study (LUCD:NASDAQ) - Seeking Alpha
NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD - StreetInsider
Breakthrough: NCI Study Validates EsoGuard's Perfect Accuracy for Early Cancer Detection$60B Market Impact - Stock Titan
Ascendiant Capital Markets Forecasts Strong Price Appreciation for PAVmed (NASDAQ:PAVM) Stock - The AM Reporter
PAVmed (NASDAQ:PAVM) Price Target Raised to $19.50 at Ascendiant Capital Markets - Defense World
PAVmed Files Prospectus Relates To Potential Offer, Sale From Time To Time Of 3.3 Million Shares Of Common Stock By Selling Stockholders - marketscreener.com
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume - ADVFN
PAVmed Provides Business Update and Second Quarter 2024 Financial Results - ADVFN
Lucid Diagnostics finalizes public offering of common stock - Medical Buyer
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock - The Bradford Era
Lucid Diagnostics Closes $16.1 Million Public Offering - MSN
PAVmed (PAVM) Stock Price, News & Analysis - MarketBeat
PAVmed subsidiary completes $16.1M stock offering By Investing.com - Investing.com Canada
PAVmed subsidiary completes $16.1M stock offering - Investing.com Australia
Lucid Diagnostics completes $16.1 million stock offering By Investing.com - Investing.com South Africa
Lucid Diagnostics Raises $16.1 Mln Through Public Offering To Support Corporate Growth - Nasdaq
Lucid Diagnostics Announces Closing of Public Offering of Common Stock - GuruFocus
Lucid Diagnostics completes $16.1 million stock offering - Investing.com Australia
Indo-Asian News Service - Indo-Asian News Service (IANS)
Lucid Diagnostics Announces Public Stock Offering - TipRanks
Lucid Diagnostics Announces Proposed Public Offering of Common Stock - The Malaysian Reserve
Lucid Diagnostics announces proposed public offering of common stock - MSN
Medical Diagnostics Pioneer Lucid Secures $15M Strategic Financing Round - Stock Titan
Lucid Diagnostics plans stock offering to boost capital By Investing.com - Investing.com South Africa
Lucid Diagnostics Announces Proposed Public Offering of Common S - GuruFocus
Pavmed Inc (PAVM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.85%
0.22%
자본화:
|
볼륨(24시간):